BIOMAT Database Logo BIOMAT Database Logo

Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus. 2000

C G Murphy, and W T Lucas, and R E Means, and S Czajak, and C L Hale, and J D Lifson, and A Kaur, and R P Johnson, and D M Knipe, and R C Desrosiers
Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, Massachusetts 02115-5716, USA.

An effective vaccine for AIDS may require development of novel vectors capable of eliciting long-lasting immune responses. Here we report the development and use of replication-competent and replication-defective strains of recombinant herpes simplex virus (HSV) that express envelope and Nef antigens of simian immunodeficiency virus (SIV). The HSV recombinants induced antienvelope antibody responses that persisted at relatively stable levels for months after the last administration. Two of seven rhesus monkeys vaccinated with recombinant HSV were solidly protected, and another showed a sustained reduction in viral load following rectal challenge with pathogenic SIVmac239 at 22 weeks following the last vaccine administration. HSV vectors thus show great promise for being able to elicit persistent immune responses and to provide durable protection against AIDS.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008253 Macaca mulatta A species of the genus MACACA inhabiting India, China, and other parts of Asia. The species is used extensively in biomedical research and adapts very well to living with humans. Chinese Rhesus Macaques,Macaca mulatta lasiota,Monkey, Rhesus,Rhesus Monkey,Rhesus Macaque,Chinese Rhesus Macaque,Macaca mulatta lasiotas,Macaque, Rhesus,Rhesus Macaque, Chinese,Rhesus Macaques,Rhesus Macaques, Chinese,Rhesus Monkeys
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D014613 Vaccines, Attenuated Live vaccines prepared from microorganisms which have undergone physical adaptation (e.g., by radiation or temperature conditioning) or serial passage in laboratory animal hosts or infected tissue/cell cultures, in order to produce avirulent mutant strains capable of inducing protective immunity. Attenuated Vaccine,Vaccines, Live, Attenuated,Attenuated Vaccines,Vaccine, Attenuated
D014614 Vaccines, Synthetic Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified. Antigens, Synthetic,Chemical Vaccine,Chemical Vaccines,Immunogens, Synthetic,Molecular Vaccine,Molecular Vaccines,Recombinant Vaccine,Semisynthetic Vaccine,Semisynthetic Vaccines,Synthetic Antigen,Synthetic Vaccine,Synthetic Vaccines,Vaccines, Recombinant,Synthetic Antigens,Synthetic Immunogens,Vaccines, Chemical,Vaccines, Molecular,Vaccines, Semisynthetic,Antigen, Synthetic,Recombinant Vaccines,Vaccine, Chemical,Vaccine, Molecular,Vaccine, Recombinant,Vaccine, Semisynthetic,Vaccine, Synthetic
D014759 Viral Envelope Proteins Integral membrane proteins that are incorporated into the VIRAL ENVELOPE. They are glycosylated during VIRAL ASSEMBLY. Envelope Proteins, Viral,Viral Envelope Glycoproteins,Viral Envelope Protein,Virus Envelope Protein,Virus Peplomer Proteins,Bovine Leukemia Virus Glycoprotein gp51,Hepatitis Virus (MHV) Glycoprotein E2,LaCrosse Virus Envelope Glycoprotein G1,Simian Sarcoma Virus Glycoprotein 70,Viral Envelope Glycoprotein gPr90 (Murine Leukemia Virus),Viral Envelope Glycoprotein gp55 (Friend Virus),Viral Envelope Proteins E1,Viral Envelope Proteins E2,Viral Envelope Proteins gp52,Viral Envelope Proteins gp70,Virus Envelope Proteins,Envelope Glycoproteins, Viral,Envelope Protein, Viral,Envelope Protein, Virus,Envelope Proteins, Virus,Glycoproteins, Viral Envelope,Peplomer Proteins, Virus,Protein, Viral Envelope,Protein, Virus Envelope,Proteins, Viral Envelope,Proteins, Virus Envelope,Proteins, Virus Peplomer
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015302 Simian Immunodeficiency Virus Species of the genus LENTIVIRUS, subgenus primate immunodeficiency viruses (IMMUNODEFICIENCY VIRUSES, PRIMATE), that induces acquired immunodeficiency syndrome in monkeys and apes (SAIDS). The genetic organization of SIV is virtually identical to HIV. SIV (Simian immunodeficiency virus),Immunodeficiency Viruses, Simian,Simian Immunodeficiency Viruses,Immunodeficiency Virus, Simian
D016097 Simian Acquired Immunodeficiency Syndrome Acquired defect of cellular immunity that occurs naturally in macaques infected with SRV serotypes, experimentally in monkeys inoculated with SRV or MASON-PFIZER MONKEY VIRUS; (MPMV), or in monkeys infected with SIMIAN IMMUNODEFICIENCY VIRUS. AIDS, Simian,SAIDS,Simian AIDS,Simian Acquired Immune Deficiency Syndrome,Simian Acquired Immuno-Deficiency Syndrome,AIDSs, Simian,Simian AIDSs,Simian Acquired Immuno Deficiency Syndrome

Related Publications

C G Murphy, and W T Lucas, and R E Means, and S Czajak, and C L Hale, and J D Lifson, and A Kaur, and R P Johnson, and D M Knipe, and R C Desrosiers
Vaccine protection against simian immunodeficiency virus infection.
August 1989, Proceedings of the National Academy of Sciences of the United States of America,
C G Murphy, and W T Lucas, and R E Means, and S Czajak, and C L Hale, and J D Lifson, and A Kaur, and R P Johnson, and D M Knipe, and R C Desrosiers
Vaccine protection against simian immunodeficiency virus in monkeys using recombinant gamma-2 herpesvirus.
December 2011, Journal of virology,
C G Murphy, and W T Lucas, and R E Means, and S Czajak, and C L Hale, and J D Lifson, and A Kaur, and R P Johnson, and D M Knipe, and R C Desrosiers
Wanted: correlates of vaccine-induced protection against simian immunodeficiency virus.
May 2008, Current opinion in HIV and AIDS,
C G Murphy, and W T Lucas, and R E Means, and S Czajak, and C L Hale, and J D Lifson, and A Kaur, and R P Johnson, and D M Knipe, and R C Desrosiers
Vaccine protection of rhesus macaques against simian immunodeficiency virus infection.
November 1990, AIDS research and human retroviruses,
C G Murphy, and W T Lucas, and R E Means, and S Czajak, and C L Hale, and J D Lifson, and A Kaur, and R P Johnson, and D M Knipe, and R C Desrosiers
Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine.
March 1996, Journal of virology,
C G Murphy, and W T Lucas, and R E Means, and S Czajak, and C L Hale, and J D Lifson, and A Kaur, and R P Johnson, and D M Knipe, and R C Desrosiers
Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine.
April 2002, Journal of virology,
C G Murphy, and W T Lucas, and R E Means, and S Czajak, and C L Hale, and J D Lifson, and A Kaur, and R P Johnson, and D M Knipe, and R C Desrosiers
Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes.
May 1987, The Journal of infectious diseases,
C G Murphy, and W T Lucas, and R E Means, and S Czajak, and C L Hale, and J D Lifson, and A Kaur, and R P Johnson, and D M Knipe, and R C Desrosiers
Preliminary report: protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine.
January 1990, Lancet (London, England),
C G Murphy, and W T Lucas, and R E Means, and S Czajak, and C L Hale, and J D Lifson, and A Kaur, and R P Johnson, and D M Knipe, and R C Desrosiers
Expression of herpes simplex virus 1 glycoprotein B by a recombinant vaccinia virus and protection of mice against lethal herpes simplex virus 1 infection.
August 1987, Proceedings of the National Academy of Sciences of the United States of America,
C G Murphy, and W T Lucas, and R E Means, and S Czajak, and C L Hale, and J D Lifson, and A Kaur, and R P Johnson, and D M Knipe, and R C Desrosiers
Vaccine protection by a triple deletion mutant of simian immunodeficiency virus.
June 1996, Journal of virology,
Copied contents to your clipboard!